Chiva short films on children and HIV shortlisted for charity award
12 December 2024. Related: Paediatric care, Treatment advocacy, On the web.
Paediatric care
Management of drug resistance to integrase inhibitors: results from an international perinatal virtual clinic
1 November 2024. Related: Treatment access, Paediatric care, Drug resistance.
CHIVA resources for children living with HIV
13 June 2024. Related: Paediatric care, On the web.
Review of US PEPFAR programme highlights continued higher infant mortality
1 December 2023. Related: Paediatric care, Other news.
IAS 2023: In-utero tenofovir-based PrEP has no effect on children’s bone mineral density
1 October 2023. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
IAS 2023: CHAPAS-4 supports better second-line options for children
1 September 2023. Related: Conference reports, Paediatric care.
No vertical HIV transmissions in the UK from women eligible for supported breastfeeding
1 August 2023. Related: Conference reports, Pregnancy, Paediatric care.
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study
10 March 2023. Related: Conference reports, Pregnancy, Paediatric care.
EU recommends approval of dispersible abacavir/lamivudine/dolutegravir FDC for children weighing 14 to >25 kg
1 December 2022. Related: Antiretrovirals, Paediatric care.
First paediatric pharmacokinetic data of dolutegravir in combination with a TAF-based NRTI backbone
3 October 2022. Related: Conference reports, Paediatric care.
VRC01 added to early ART in infants did not reduce viral reservoir
1 September 2022. Related: Conference reports, Paediatric care.
Using PrEP during pregnancy is safe for children
1 September 2022. Related: Conference reports, Pregnancy, Paediatric care.
Dolutegravir-based ART in children and adolescents: effective in six African countries
3 August 2022. Related: Conference reports, Antiretrovirals, Treatment strategies, Paediatric care.
Dual bNAbs in children: dose-finding and safety data on VRC01LS and 10-1074 in the Tatelo study
1 July 2022. Related: Paediatric care.
CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
1 March 2022. Related: Conference reports, Paediatric care, Cure-related research.
Substudies from the ODYSSEY trial: results July 2021
17 September 2021. Related: Conference reports, Paediatric care.
13th International Workshop on HIV Paediatrics 2021
1 August 2021. Related: Conference reports, Paediatric care.
Dolutegravir superior to standard-of-care in young children: results from the ODYSSEY trial
1 August 2021. Related: Conference reports, Paediatric care.
Dolutegravir superior to standard of care in children and adolescents: results from the ODYSSEY trial
1 June 2021. Related: Conference reports, Paediatric care.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.
New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1
24 February 2021. Related: Conference reports, Paediatric care.
Dolutegravir dosing for infants and young children
9 December 2020. Related: Conference reports, Paediatric care.
EU approves dolutegravir 5 mg dispersible for children older than four weeks
9 December 2020. Related: Antiretrovirals, Paediatric care.
New formulation of dolutegravir will make modern ART available for babies and young children at less than $120 a year
9 December 2020. Related: Antiretrovirals, Treatment access, Paediatric care.
New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet
11 November 2020. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Levels of long-acting anti-HIV bNAb high in infants after 1 or 2 doses – but not high enough
14 October 2020. Related: Conference reports, Paediatric care, PK and drug interactions, HIV prevention and transmission.
Paediatric dolutegravir dosing at AIDS 2020
28 August 2020. Related: Conference reports, Paediatric care.
FDA approves dolutegravir formulations to treat infants and young children
26 June 2020. Related: Antiretrovirals, Paediatric care.
Dolutegravir for younger children: results from the ODYSSEY trial
23 August 2019. Related: Conference reports, Paediatric care.
B/F/TAF suitable for children from six years of age
20 May 2019. Related: Conference reports, Paediatric care.
Paediatric dolutegravir update
30 April 2019. Related: Conference reports, Paediatric care.
No significant decrease in raltegravir free fraction during pregnancy
12 December 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
No additional neural tube defects with preconception dolutegravir: data from three birth outcome cohorts
13 November 2018. Related: Conference reports, Pregnancy, Paediatric care.
Why U=U does not cover breastfeeding
13 November 2018. Related: Conference reports, Paediatric care.
Dolutegravir dispersible tablets for infants and young children: early PK, safety and efficacy
24 August 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
10th International Workshop on HIV Paediatrics – first reports
3 August 2018. Related: Conference reports, Paediatric care.
Etravirine dispersible paediatric tablet has greater bioavailability when dispersed in water compared to swallowed whole
29 June 2018. Related: Conference reports, Paediatric care, PK and drug interactions.
Dispersible paediatric versions of dolutegravir provide higher bioavailability than immediate release formulations
8 June 2018. Related: Conference reports, Paediatric care.
FDA guidance for developing paediatric ARVs: online for comment (2018)
21 May 2018. Related: Paediatric care, Guidelines.
Switch to TAF appears safe and effective in adolescents: similar PK to adults
16 April 2018. Related: Conference reports, Paediatric care.
Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6
16 April 2018. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
FDA approves raltegravir for newborns
5 January 2018. Related: Antiretrovirals, Paediatric care.
Earlier ART reduces infant mortality in South Africa but risk of death and loss to follow up still high
28 November 2017. Related: Conference reports, Paediatric care.
Long-acting ART for children is a deferred priority despite achievable dosing
28 November 2017. Related: Antiretrovirals, Paediatric care.
9th International Workshop on HIV Paediatrics, 21–22 July 2017, Paris
10 August 2017. Related: Conference reports, Paediatric care.
Chewable raltegravir tablets can be crushed and dispersed in liquid for young children
10 August 2017. Related: Conference reports, Paediatric care.
FDA approves sofosbuvir/ledipasvir and sofosbuvir for children aged 12 to 17
26 June 2017. Related: Paediatric care, Hepatitis coinfection.
Community presentations: dental care, HIV awareness and access to formula milk
24 April 2017. Related: Conference reports, Paediatric care.
VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding
24 April 2017. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
Tenofovir alafenamide exposure is modestly higher in children than adults
24 April 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
New HIV diagnoses in children in UK and Ireland continue to decline
24 April 2017. Related: Conference reports, Paediatric care, PK and drug interactions, Diagnostics.
World Health Organisation paediatric dosing tool
24 April 2017. Related: Conference reports, Paediatric care, PK and drug interactions.
Dolutegravir exposure increases when fixed dose combination tablets are crushed
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
Pharmacokinetics, safety and efficacy of dolutegravir in very young children
27 February 2017. Related: Conference reports, Antiretrovirals, Paediatric care.
FDA approves maraviroc for children aged two and older
29 November 2016. Related: Antiretrovirals, Paediatric care.
Raltegravir-based third-line ART in children and adolescents
1 October 2016. Related: Conference reports, Antiretrovirals, Paediatric care.
Raltegravir in HIV-exposed neonates
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Virological response without routine viral load monitoring in children: results from the ARROW trial
1 October 2016. Related: Conference reports, Paediatric care.
Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s
1 October 2016. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence
1 August 2016. Related: Conference reports, Pregnancy, Paediatric care, HIV prevention and transmission.
No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial
1 August 2016. Related: Conference reports, Paediatric care, Drug resistance.
Shortened nine-month MDR-TB treatment works well in children and adolescents
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB
1 August 2016. Related: Conference reports, Paediatric care, TB coinfection.
The paediatric antiretroviral pipeline
14 July 2016. Related: Pipeline report, Antiretrovirals, Paediatric care.